Radiopharm Theranostics begins third-cohort enrolment in Phase 1 ¹⁷⁷Lu-RAD204 trial targeting PD-L1 tumours

Radiopharm Theranostics Ltd (ASX: RAD, NASDAQ: RADX) has initiated enrolment for the third cohort in its ongoing Phase 1 dose-escalation trial of ¹⁷⁷Lu-RAD204, a novel single-domain antibody (sdAb) radioligand targeting PD-L1 in advanced solid tumours. The escalation follows approval from the Data and Safety Monitoring Committee (DSMC) after favourable safety and biodistribution data from the first two cohorts. The committee has now cleared the study to progress to the 90 mCi dose level, marking a pivotal step in the program’s early-stage development.

How Radiopharm Theranostics’ ¹⁷⁷Lu-RAD204 could redefine PD-L1-targeted radiotherapy across multiple tumour types

The Phase 1 open-label trial (ClinicalTrials.gov ID: NCT06305962) is designed to assess the safety, tolerability, and tumour uptake of ¹⁷⁷Lu-RAD204 in patients with PD-L1-positive metastatic or advanced solid tumours. The candidate is being evaluated across a diverse group of cancer types including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), and endometrial cancer.

¹⁷⁷Lu-RAD204 employs a single-domain antibody fragment engineered to bind precisely to the PD-L1 receptor expressed on tumour cells. Once bound, the attached lutetium-177 isotope delivers a therapeutic dose of beta radiation to malignant tissue, aiming to destroy cancer cells while minimizing collateral damage to surrounding healthy tissue. The therapeutic concept builds on the proven targeting capabilities of immune checkpoint inhibitors but adds a cytotoxic radiopharmaceutical component that may overcome resistance seen in patients who fail to respond to standard immunotherapies.

Radiopharm’s early cohorts demonstrated consistent tumour uptake on SPECT imaging and no dose-limiting toxicities. These findings prompted DSMC approval to escalate to 60 mCi for cohort 2, and now to 90 mCi for cohort 3. The incremental dosing strategy aims to balance safety with effective radiation delivery, generating key dosimetry data required to design subsequent Phase 1b or Phase 2 studies.

Why Radiopharm Theranostics’ third-cohort escalation signals growing confidence in its radiopharmaceutical platform

Radiopharm Theranostics’ decision to escalate to the third cohort reinforces confidence in both its PD-L1-targeting technology and its broader radiopharmaceutical development platform. The company has been advancing a diversified pipeline of precision oncology assets, including RAD202 (a HER2-targeting agent) and RAD101 (a brain-metastasis imaging program).

Management indicated that the transition to the higher dose was based on safety validation and measurable tumour uptake, suggesting that ¹⁷⁷Lu-RAD204’s radiation profile is within the expected therapeutic window. This type of milestone typically attracts investor attention, as moving from early dosing stages to clinically meaningful thresholds often serves as a proxy for early efficacy signals.

The company’s internal theranostic model—combining diagnostic and therapeutic imaging in one development pipeline—allows it to observe drug biodistribution in real time. By leveraging its proprietary platform, Radiopharm aims to shorten timelines between early-phase readouts and pivotal-stage trials. Such a strategy could offer a competitive edge in the crowded radiopharma space, which has seen rising interest following the commercial success of radioligand therapies like Pluvicto® and Lutathera®.

How trial progression could influence investor sentiment and valuation in the radiopharmaceutical sector

Investor sentiment toward Radiopharm Theranostics has gradually strengthened following its U.S. dual-listing and steady progress across multiple programs. Shares of RADX on NASDAQ and RAD on the ASX have reflected the company’s execution milestones more than short-term volatility, with the enrolment announcement likely to support positive momentum among institutional traders focused on early oncology catalysts.

In capital markets, dose-escalation approvals typically reflect regulator-aligned safety validation—viewed as a gateway to higher-value inflection points such as first-in-human efficacy data or imaging confirmation of tumour regression. If ¹⁷⁷Lu-RAD204’s 90 mCi cohort produces favourable dosimetry and tolerability outcomes, Radiopharm could accelerate plans for an expansion cohort or a Phase 2a signal-seeking trial.

That momentum would also enhance its partnership potential, especially as larger pharma companies seek to enter the radioligand therapy segment through strategic licensing or co-development agreements. The sector’s resurgence has drawn notable M&A activity, from Eli Lilly’s acquisition of POINT Biopharma to Novartis’s expansion in Pluvicto manufacturing. Radiopharm’s ability to demonstrate proof-of-mechanism at scale could position it among the next generation of radiotheranostic innovators competing in PD-L1-targeted oncology.

What the Phase 1 outcomes may reveal about the competitive positioning of ¹⁷⁷Lu-RAD204 and the future of PD-L1 radioligands

Beyond immediate safety and biodistribution findings, the ¹⁷⁷Lu-RAD204 study could help define the role of PD-L1 radioligands in precision oncology. Current PD-L1 blockade therapies, while effective in some settings, leave a significant subset of patients unresponsive due to immune evasion or low biomarker expression. Radiopharm’s approach could address this gap by using radiation to directly kill PD-L1-positive tumour cells independent of immune activation.

If the third-cohort results demonstrate selective uptake with manageable marrow and renal radiation exposure, the data could reshape how PD-L1 expression is leveraged—not just as a predictive biomarker but as a direct therapeutic target. The implications extend to multiple cancer types, especially those where immune checkpoint inhibition has plateaued.

The oncology community will also watch for cross-trial insights, such as whether RAD204’s biodistribution patterns correlate with FDG-PET imaging, potentially improving patient selection and response prediction. By combining these modalities, Radiopharm may advance a theranostic pairing capable of delivering both imaging and treatment through one precision-guided pathway—a hallmark of the company’s development ethos.

How Radiopharm’s broader strategy integrates financial resilience and clinical scalability

Financially, Radiopharm Theranostics has maintained disciplined capital management amid a challenging funding environment for biotech firms. The company’s U.S. listing broadened its investor base, while recent financing activities strengthened its cash runway to support continued development of ¹⁷⁷Lu-RAD204 and other pipeline assets.

Operationally, securing lutetium-177 supply and ensuring radiopharmaceutical manufacturing compliance remain critical as the program scales. Radiopharm has signed agreements with specialized isotope suppliers to de-risk logistics for future clinical and commercial expansion.

The company’s diversified pipeline across oncology subtypes also serves as a hedge against clinical attrition. Each program—diagnostic or therapeutic—feeds into a shared radiochemistry platform, enhancing efficiency and data cross-utilization. Should ¹⁷⁷Lu-RAD204 show compelling results, the same targeting and radiolabelling principles could be replicated across other tumour markers, accelerating portfolio growth.

What investors and clinicians can expect as the ¹⁷⁷Lu-RAD204 program advances into higher-dose evaluation

Radiopharm Theranostics’ progression into the third dose-escalation cohort highlights not just regulatory diligence but also the company’s growing confidence in its scientific and operational capabilities. In the highly specialized field of radiopharmaceuticals, incremental dose escalation represents more than a routine safety check—it signifies proof that the therapy’s biodistribution, radiochemistry, and organ tolerance align with preclinical expectations. Each cohort adds critical human data on radiation kinetics, tumour targeting efficiency, and off-target exposure, informing both clinical design and potential partnerships.

Industry observers have noted that Radiopharm’s program development cadence has been remarkably consistent despite global supply challenges for lutetium-177 and isotope production constraints. This continuity reflects a maturing infrastructure that many early-stage peers struggle to sustain. As the company transitions into higher-dose testing, the ability to manage radioligand logistics, imaging coordination, and clinical data flow becomes a differentiating factor that could enhance investor trust and partner appeal.

If the third-cohort data confirm selective tumour uptake and a tolerable safety margin, Radiopharm could pursue several strategic pathways—expanding into tumour-specific Phase 2 studies, exploring combination regimens with checkpoint inhibitors, or attracting co-development interest from large pharmaceutical groups seeking entry into PD-L1-directed radiotherapeutics. Such developments could shift the firm’s profile from a niche biotech to a contender in the next wave of oncology innovation, where radioligands meet precision immunotherapy.

In the near term, the company’s ability to communicate interim findings with transparency will be essential to maintaining momentum. Clear clinical timelines, updates on isotope supply security, and visibility into broader platform synergies will continue to shape market confidence. For Radiopharm Theranostics, this third cohort is not merely a procedural milestone—it is the bridge between scientific validation and commercial credibility, potentially setting the stage for a breakthrough year in radiopharmaceutical oncology.